# A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)

> **NCT04395456** · PHASE2 · UNKNOWN · sponsor: **Amyndas Pharmaceuticals S.A.** · enrollment: 144 (estimated)

## Conditions studied

- Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)

## Interventions

- **DRUG:** AMY-101
- **OTHER:** WFI 5% glucose

## Key facts

- **NCT ID:** NCT04395456
- **Lead sponsor:** Amyndas Pharmaceuticals S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09
- **Primary completion:** 2022-09
- **Final completion:** 2022-12
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04395456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04395456, "A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04395456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*